- Home
- TACT vs NRXP Comparison
TACT vs NRXP Comparison
Compare TACT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- NRXP
- Stock Information
- Founded
- TACT 1996
- NRXP 2015
- Country
- TACT United States
- NRXP United States
- Employees
- TACT N/A
- NRXP N/A
- Industry
- TACT Computer peripheral equipment
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- NRXP Health Care
- Exchange
- TACT Nasdaq
- NRXP Nasdaq
- Market Cap
- TACT 44.1M
- NRXP 51.3M
- IPO Year
- TACT 1996
- NRXP N/A
- Fundamental
- Price
- TACT $3.93
- NRXP $2.17
- Analyst Decision
- TACT Strong Buy
- NRXP Strong Buy
- Analyst Count
- TACT 1
- NRXP 3
- Target Price
- TACT $7.50
- NRXP $31.67
- AVG Volume (30 Days)
- TACT 13.6K
- NRXP 245.6K
- Earning Date
- TACT 03-18-2025
- NRXP 03-27-2025
- Dividend Yield
- TACT N/A
- NRXP N/A
- EPS Growth
- TACT N/A
- NRXP N/A
- EPS
- TACT N/A
- NRXP N/A
- Revenue
- TACT $46,418,000.00
- NRXP N/A
- Revenue This Year
- TACT N/A
- NRXP N/A
- Revenue Next Year
- TACT $16.86
- NRXP N/A
- P/E Ratio
- TACT N/A
- NRXP N/A
- Revenue Growth
- TACT N/A
- NRXP N/A
- 52 Week Low
- TACT $3.32
- NRXP $1.10
- 52 Week High
- TACT $7.13
- NRXP $7.20
- Technical
- Relative Strength Index (RSI)
- TACT 36.84
- NRXP 39.89
- Support Level
- TACT $3.75
- NRXP $1.84
- Resistance Level
- TACT $4.13
- NRXP $2.28
- Average True Range (ATR)
- TACT 0.21
- NRXP 0.22
- MACD
- TACT -0.03
- NRXP -0.03
- Stochastic Oscillator
- TACT 25.71
- NRXP 29.26
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.